A.M. Schoepfer

Discipline

Psychologie (5) Economies et finances (2) Science politique (1) Education (1)

Type de document

Articles (18) Recensions (4)

Co-auteur

Date

Source

Mot-clé

Patients (13) Patients (13) maladie (11) maladie (11) Human beings (10) Treatment (9) adulte (8) adulte (8) Diagnosis (7) Diagnosis (7) Inflammatory bowel diseases (6) thérapie (5) Ulcerative colitis (5) Therapeutics (5) Symptoms (5) Swiss (5) cohorte (5) puits (4) enfant (4) Inhibitors (4) Regression analysis (4) Evaluation (4) Deglutition disorders (4) Colitis (4) Older people (4) Pathogenesis (4) nourisson (3) temps (durée) (3) sécurité (3) Development (3)

Documents écrit par A.M. Schoepfer (18) | parle de A.M. Schoepfer (0)

Eosinophilic Esophagitis beyond Eosinophils - an Emerging Phenomenon Overlapping with Eosinophilic Esophagitis: Collegium Internationale Allergologicum (CIA) Update 2023.
V.S. Salvador Nunes et al. (2023)
Fluticasone Propionate Orally Disintegrating Tablet (APT-1011) for Eosinophilic Esophagitis: Randomized Controlled Trial.
E.S. Dellon et al.
Impact of Diagnostic Delay on Disease Course in Pediatric- versus Adult-Onset Patients with Ulcerative Colitis: Data from the Swiss IBD Cohort.
A.M. Schoepfer et al.
Development of a core outcome set for therapeutic studies in eosinophilic esophagitis (COREOS).
C. Ma et al.
Increasing Incidence of Microscopic Colitis in a Population-Based Cohort Study in Switzerland.
H. Maye et al.
Gastroentérologie et hépatologie [Advances in gastroenterology and hepatology 2020]
F. Artru et al. (13 janv. 2021)
RPC4046, a Monoclonal Antibody Against IL13, Reduces Histologic and Endoscopic Activity in Patients With Eosinophilic Esophagitis.
I. Hirano et al.
Frequency and type of drug-related side effects necessitating treatment discontinuation in the Swiss Inflammatory Bowel Disease Cohort.
S. Godat et al.
Expression Patterns of TNFα, MAdCAM1, and STAT3 in Intestinal and Skin Manifestations of Inflammatory Bowel Disease.
S.R. Vavricka et al. (28 févr. 2018)
Low serum zinc levels predict presence of depression symptoms, but not overall disease outcome, regardless of ATG16L1 genotype in Crohn's disease patients.
T. Greuter et al. (2018)
Trends in prevalence, mortality, health care utilization and health care costs of Swiss IBD patients: a claims data based study of the years 2010, 2012 and 2014.
C. Bähler et al. (2 déc. 2017)
Mise au point sur la rectocolite ulcéro-hémorragique en 2017 [Management of ulcerative colitis in 2017]
E. Moschouri et al. (30 août 2017)
Extraintestinal Manifestations of Pediatric Inflammatory Bowel Disease: Prevalence, Presentation, and Anti-TNF Treatment.
T. Greuter et al.
Current concepts in eosinophilic esophagitis.
D. Simon et al. (2017)
Comparison of different biopsy forceps models for tissue sampling in eosinophilic esophagitis.
C. Bussmann et al.
Prevalence and risk factors for therapy escalation in ulcerative colitis in the Swiss IBD Cohort Study
E. Safroneeva et al. (2015)
Therapie der CED bei Steroidversagen : Immunsuppressiva oder Biologika? [Therapy of steroid resistant inflammatory bowel disease Immunomodulators or biologicals?]
M. Manz et al.
Development and validation of a symptom-based activity index for adults with eosinophilic esophagitis.
A.M. Schoepfer et al. (2014)